Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 2/20 | 0.45 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | PNMT | P11086 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 6/20 | 0.37 |
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | PRCP | P42785 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21744420 | 0.86 | CD44 (0.47) | CD44TLR9TLR7PNMTMAOB | |
| SCHEMBL21744696 | 0.83 | CD44 (0.45) | CD44TLR9TLR7PNMTMAOB | |
| SCHEMBL21743785 | 0.81 | CD44 (0.53) | CD44TLR9TLR7PNMTMAOB | |
| SCHEMBL21744163 | 0.81 | CD44 (0.45) | CD44TLR9TLR7PNMTMAOB | |
| SCHEMBL21743758 | 0.80 | CXCR4 (0.46) | CD44TLR9TLR7PNMTMAOB | |
| SCHEMBL21744413 | 0.79 | TLR9 (0.44) | CD44TLR9TLR7PNMTMAOB | |
| SCHEMBL21744260 | 0.79 | CD44 (0.46) | CD44TLR9TLR7PNMTMAOB | |
| SCHEMBL1011153 | 0.78 | CD44 (0.49) | CD44TLR9TLR7PNMTMAOB | |
| SCHEMBL21743760 | 0.78 | TLR9 (0.49) | CD44TLR9TLR7PNMTMAOB | |
| SCHEMBL21744394 | 0.76 | HTR2C (0.54) | CD44PNMTMAOBHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230112832-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | UNIV EMORY (US) | 2023-04-13 | — | — | US | disclosed |
| US-20200054623-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | EMORY UNIVERSITY | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054623-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | CXCR4, CXCL12, CXCR1 | CD44 407/4885TLR9 138/4885TLR7 135/4885 |
| US-20230112832-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | CXCR4, CXCL12, CXCR1 | CD44 407/4885TLR9 138/4885TLR7 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.